Skip to main content

Table 1 Baseline characteristics of patients enrolled in a pilot treatment program for chronic hepatitis B, Addis Ababa, Ethiopia

From: Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

  All patients
(n = 1303)
Eligible for treatment
(n = 328)
Not eligible for treatment
(n = 962)a
 
Number (%) Number (%) Number (%) P
Men 770 (59.1) 260 (79.3) 500 (52.0) < 0.001
Age (years)     0.006
 18–25 286 (21.9) 64 (19.5) 220 (22.9)
 26–35 549 (42.1) 122 (37.2) 424 (44.1)
 36–45 289 (22.2) 83 (25.3) 202 (21.0)
 > 45 179 (13.7) 59 (18.0) 116 (12.1)
Marital status     0.667
 Single 457 (35.1) 117 (35.7) 338 (35.1)
 Married 796 (61.1) 201 (61.3) 584 (60.7)
 Divorced/widowed 50 (3.8) 10 (3.0) 40 (4.2)
ALT, U/Lb     < 0.001
 < 40 1014 (78.9) 185 (57.3) 818 (86.2)
 40–79 201 (15.6) 91 (28.2) 108 (11.4)
 ≥ 80 70 (5.4) 47 (14.6) 23 (2.4)
HBV viral load, IU/mLc     < 0.001
 < 2000 722 (56.5) 107 (33.1) 608 (64.5)
 2000–19,999 256 (20.0) 46 (14.2) 208 (22.1)
 ≥ 20,000 301 (23.5) 170 (52.6) 127 (13.5)
Transient elastography, kPad     < 0.001
 < 8.0 879 (74.0) 46 (15.0) 825 (94.5)
 8.0–9.9 67 (5.6) 39 (12.7) 27 (3.1)
 ≥ 10.0 242 (20.4) 221 (72.2) 21 (2.4)
Co-infections
 Anti-HCV positive 28 (2.1) 7 (3.2) 21 (2.6) 0.619
 Anti-HDV positive 19 (1.4) 10 (5.9) 9 (1.0) < 0.001
APRI, median (IQR)e 0.24 (0.17–0.36) 0.48 (0.27–0.90) 0.21 (0.16–0.29) < 0.001
FIB-4, median (IQR)f 0.56 (0.41–0.79) 1.06 (0.61–1.91) 0.55 (0.41–0.76) < 0.001
  1. ALT alanine aminotransferase, HBV hepatitis B virus, HCV hepatitis C virus, HDV hepatitis D virus, APRI aspartate aminotransferase to platelet ratio index, IQR interquartile range
  2. a13 patients were already on treatment and could not be assessed for treatment eligibility
  3. b18 results missing
  4. c 24 results missing
  5. d111 results missing
  6. e124 results missing
  7. f128 results missing